Jason Shafrin, PhD – USC Schaeffer

Recent Work

A Strategy for Value-Based Drug Pricing Under the Inflation Reduction Act

To make sure that CMS is getting its money’s worth for today’s drugs, it must ensure that the maximum fair price is aligned to drug value.

By Jason Shafrin, PhD, Darius Lakdawalla, PhD, Jalpa A. Doshi, PhD, Louis P. Garrison, PhD, Anup Malani, PhD, Peter J. Neumann, ScD, Charles E. Phelps, PhD, Adrian Towse, MA, MPhil and Richard J. Willke, PhD
Categorized in
- Articles
- Perspective
Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market

This paper provides three recommendations to steer the potential effects of the IRA toward its goal of improving patient access while encouraging innovation.
Categorized in
- Research
- White Paper